Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tasly Pharmaceutical Group Co., Ltd (600535.SS)
Tianjin, CN
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.81% | -0.78% | -7.01% | -2.90% | -8.22% | -6.64% | -13.84% | -10.67% | -3.10% | -44.56% | +441.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 10 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-3.1% Q1'26: +5.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.6% Q1'26: +19.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.3% Q1'26: +19.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.3% ★ Q1'26: +20.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.5% ★ Q1'26: +12.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.85× ★ Q1'26: 0.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.23B
est: 13.45B (-1.6%)
|
13.95B
est: 13.80B (+1.1%)
|
16.09B
est: 15.70B (+2.5%)
|
17.99B
est: 18.36B (-2.0%)
|
19.00B
est: 19.69B (-3.5%)
|
13.58B
est: 13.51B (+0.5%)
|
7.95B
est: 7.72B (+3.0%)
|
8.64B
est: 8.53B (+1.3%)
|
8.67B
est: 8.65B (+0.2%)
|
8.50B
est: 8.74B (-2.7%)
|
8.24B
est: 8.81B (-6.5%)
|
8.99B
8.72B – 9.11B
+2.0% YoY
|
9.87B
9.27B – 10.31B
+9.8% YoY
|
10.84B
10.82B – 10.85B
+9.8% YoY
|
| EBITDA |
2.36B
est: 2.68B (-11.9%)
|
2.04B
est: 2.74B (-25.6%)
|
2.40B
est: 3.12B (-23.0%)
|
2.81B
est: 3.65B (-23.0%)
|
2.18B
est: 3.92B (-44.3%)
|
2.29B
est: 2.69B (-14.6%)
|
3.21B
est: 1.54B (+109.1%)
|
336.18M
est: 1.70B (-80.2%)
|
1.81B
est: 1.80B (+0.5%)
|
1.53B
est: 1.82B (-16.0%)
|
1.74B
est: 1.84B (-5.4%)
|
1.87B
1.82B – 1.90B
+2.0% YoY
|
2.06B
1.93B – 2.15B
+9.8% YoY
|
2.26B
2.26B – 2.26B
+9.8% YoY
|
| EBIT |
2.07B
est: 2.01B (+2.6%)
|
1.73B
est: 2.07B (-16.2%)
|
2.06B
est: 2.35B (-12.3%)
|
2.45B
est: 2.75B (-10.7%)
|
1.79B
est: 2.95B (-39.2%)
|
1.75B
est: 2.02B (-13.3%)
|
2.80B
est: 1.16B (+142.6%)
|
-97.74M
est: 1.28B (-107.7%)
|
1.31B
est: 1.36B (-4.1%)
|
1.13B
est: 1.38B (-17.7%)
|
1.34B
est: 1.39B (-3.5%)
|
1.42B
1.37B – 1.44B
+2.0% YoY
|
1.56B
1.46B – 1.63B
+9.8% YoY
|
1.71B
1.71B – 1.71B
+9.8% YoY
|
| Net Income |
1.48B
est: 1.57B (-5.6%)
|
1.18B
est: 1.42B (-17.1%)
|
1.38B
est: 1.35B (+2.0%)
|
1.55B
est: 1.57B (-1.4%)
|
1.00B
est: 1.51B (-33.7%)
|
1.13B
est: 1.04B (+8.4%)
|
2.36B
est: 1.75B (+34.5%)
|
-264.24M
est: -3.73M (-6,978.9%)
|
1.07B
est: 1.03B (+4.4%)
|
955.59M
est: 1.07B (-10.5%)
|
1.11B
est: 1.16B (-4.8%)
|
1.33B
1.22B – 1.51B
+14.3% YoY
|
1.59B
1.33B – 1.90B
+19.5% YoY
|
1.79B
1.53B – 2.13B
+13.0% YoY
|
| SGA |
2.90B
est: 4.87B (-40.4%)
|
3.21B
est: 5.00B (-35.7%)
|
3.04B
est: 5.68B (-46.5%)
|
3.36B
est: 6.65B (-49.4%)
|
3.40B
est: 7.13B (-52.2%)
|
3.21B
est: 4.89B (-34.3%)
|
3.34B
est: 2.79B (+19.5%)
|
3.27B
est: 3.09B (+5.8%)
|
3.33B
est: 3.42B (-2.7%)
|
3.33B
est: 3.45B (-3.4%)
|
3.31B
est: 3.48B (-5.0%)
|
3.55B
3.44B – 3.60B
+2.0% YoY
|
3.90B
3.66B – 4.07B
+9.8% YoY
|
4.28B
4.28B – 4.29B
+9.8% YoY
|
| EPS |
0.99
est: 1.05 (-5.6%)
|
0.78
est: 0.95 (-17.9%)
|
0.91
est: 0.90 (+0.7%)
|
1.02
est: 1.05 (-2.8%)
|
0.66
est: 1.01 (-34.8%)
|
0.75
est: 0.70 (+7.9%)
|
1.57
est: 1.17 (+33.7%)
|
-0.18
est: 0.00 (-7,100.0%)
|
0.72
est: 0.69 (+4.6%)
|
0.64
est: 0.69 (-7.1%)
|
0.74
est: 0.76 (-2.3%)
|
0.86
0.82 – 1.01
+14.1% YoY
|
1.01
0.89 – 1.27
+16.7% YoY
|
1.15
1.02 – 1.43
+13.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.10% | 37.0K | 0.65% |
| 2 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.09% | 346.9K | 0.44% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.04% | 19.4K | 0.54% |
| 4 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.03% | 5.4K | 0.65% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 173.7K | 0.19% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 27.4K | 0.19% |
| 7 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.0K | 0.15% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 110.6K | 0.46% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 248.7K | 0.39% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 193.8K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ai Chun Ju | Deputy General Manager | — | male |
| Jie Wei | Chief Financial Officer & Head of Accounting | — | female |
| Jin Yong Cai | GM & Director | — | male |
| Shui Ping Zhou | Deputy GM & Director | — | male |
| Shunnan Zhang | Deputy General Manager | — | male |
| Yiming Wang | Deputy General Manager | — | male |
| Yu Jie | Secretary & Deputy GM | — | male |
| Zhen Wang | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600535.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
